+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic analysis of patients with metastatic triple-negative breast cancer: a report of 120 cases



Prognostic analysis of patients with metastatic triple-negative breast cancer: a report of 120 cases



Zhonghua Yi Xue Za Zhi 90(40): 2848-2851



To analyze the clinical features and survival for patients with metastatic triple negative breast cancer (MTNBC), especially such a metastatic site as brain. The clinical data and survival status of 120 cases of operable MTNBC treated at our hospital from January 2002 to December 2004 were collected. SPSS 13.0 software was used for statistic treatment. Statistical significance was considered at P < 0.05. At the time of last follow-up, the median time after metastasis was 22 months. Nine deaths (65.8%) were recorded. In terms of all metastatic sites (initial + subsequent), lung (58.3%), liver (41.7%) and brain (40.8%) were most common sites. The patients with brain metastasis had a worse survival than those with non-brain metastases. Twenty-two (18.3%) patients were found to have brain metastasis at the time of first metastatic presentation. The initial metastatic site in patients with brain metastasis had a worse survival than those with non-brain metastases. The median survival time after metastasis was 8 and 31 months respectively (P = 0.000). Triple-negative breast cancer is associated with a poor survival after metastases. The patients with brain metastases have a worse survival than those with non-brain metastases. New treatment strategies are needed.

(PDF emailed within 1 workday: $29.90)

Accession: 055209061

Download citation: RISBibTeXText

PMID: 21162797


Related references

Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19(3): 246-248, 2010

Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. American Journal of Nuclear Medicine and Molecular Imaging 6(2): 120-127, 2016

Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Molecular and Clinical Oncology 2(2): 245-251, 2014

Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer. Tumour Biology 35(10): 9751-9757, 2015

Analysis of clinicopathological characteristics and prognosis for triple negative breast cancer: a report of 108 cases. Zhonghua Zhong Liu Za Zhi 30(3): 196-199, 2008

Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast Cancer Research and Treatment 139(2): 497-506, 2014

Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer. Experimental and Therapeutic Medicine 9(6): 2147-2150, 2015

Diurnal periodicity of assimilate transport shapes resource allocation and whole plant carbon balance. Plant Journal, 2018

Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. Oncology Letters 11(3): 2320-2326, 2016

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis. Breast Care 10(6): 413-416, 2016

Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 37(7): 1259-1264, 2010

Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clinical Biochemistry 42(13-14): 1420-1426, 2010

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Research and Treatment 134(1): 277-282, 2012

Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data. Oncotarget 7(44): 71620-71634, 2016

COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients. Medical Oncology 31(6): 989-989, 2015